LewisJRubinMD
Pulmonology • La Jolla, CACritical Care Medicine, Pleural Disease
Professor of Medicine, UCSD
Dr. Rubin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5550 Caminito Genio
La Jolla, CA 92037Phone+1 858-736-7542
Education & Training
Duke University HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 1978 - 1979- Duke University HospitalResidency, Internal Medicine, 1975 - 1978
Albert Einstein College of MedicineClass of 1975
Certifications & Licensure
NY State Medical License 2015 - 2026
MD State Medical License 1985 - 2017
NC State Medical License 1978 - 2017
CA State Medical License 1999 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1995
Clinical Trials
- ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) Start of enrollment: 2004 Jan 01
- Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension Start of enrollment: 2006 Aug 01
Publications & Presentations
PubMed
- 13 citationsLong-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard N. Channick, J. Gerry Coghlan, Marius M. Hoeper
Advances in Therapy. 2021-10-30 - 7 citationsComparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects.Robert Roscigno, Toby Vaughn, Ed Parsley, Thomas Hunt, Michael A. Eldon
Vascular Pharmacology. 2021-02-02 - 41 citationsIntravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility StudyAlexander M.K. Rothman, Jean-Luc Vachiery, Luke Howard, Ghada W. Mikhail, I.M. Lang
JACC. Cardiovascular Interventions. 2020-04-27
Other
- Clinical features and diagnosis of pulmonary hypertension in adultsRubin LJ, Hopkins W
http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-pulmonary-hypertension-in-adults
UpToDate, Wolters Kluwer Health - 2012-12-13 - Pathogenesis of pulmonary hypertensionRubin LJ, Hopkins W
http://www.uptodate.com/contents/pathogenesis-of-pulmonary-hypertension
UpToDate, Wolters Kluwer Health - 2012-10-22 - Treatment of pulmonary hypertension in adultsRubin LJ, Hopkins W
http://www.uptodate.com/contents/treatment-of-pulmonary-hypertension-in-adults
UpToDate, Wolters Kluwer Health - 2013-04-12 - Join now to see all
Press Mentions
Karos Pharmaceuticals Advances Development of KAR5585 to Treat Pulmonary Arterial Hypertension into the ClinicApril 13th, 2016
Pulmonary Hypertension Association (PHA) Names ‘Periwinkle Pioneers’: Honor Recognizes 25 Years of Pulmonary Hypertension (PH) AdvancementsNovember 25th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
